Moving quickly to tamp down concerns raised by the independent Data Safety Monitoring Board (DSMB) this week, AstraZeneca announced today that primary analysis of its AZD1222 COVID-19 vaccine’s phase three trial confirmed 76 percent efficacy against symptomatic cases.
“The primary analysis... Read More »
Cipla Therapeutics, and SIGA Technologies, Inc, announced Tuesday that they would be entering into a strategic partnership to deliver innovation and access to novel antibacterial drugs, particularly to fight biothreats.
According to the World Health Organization (WHO), anti-microbial resistance... Read More »
Northrop Grumman Systems and Lockheed Martin have been awarded Department of Defense (DOD) contracts supporting the Next Generation Interceptor (NGI) program.
NGI is an advanced interceptor designed to protect against intercontinental ballistic missile attacks. The DOD would ensure the overall... Read More »
A recently released Johns Hopkins Center for Health Security at the Bloomberg School of Public Health report is calling on the United States to address COVID-19 health misinformation and disinformation.
The call for a national strategy stems from the findings in "National Priorities to Combat... Read More »
Topline results from a phase three trial of the Regeneron Pharmaceuticals, Inc. COVID-19 antibody treatment, REGEN-COV, are in, demonstrating 70 percent reductions in hospitalization or death and shortened symptom durations.
The results were not overly affected by dosage. Across three dosage... Read More »
Encouraged by its success against SARS-CoV-2 and other coronaviruses in test-tube studies, Pfizer Inc. has launched a phase one study of healthy adults to determine if multiple ascending doses of an oral antiviral therapeutic could be effective against COVID-19.
PF-07321332 is a protease... Read More »
Department of Defense (DOD) officials have proceeded with transportable advanced nuclear microreactor prototype design initiatives through two contract options.
Teams led by BWXT Advanced Technologies, LLC, of Lynchburg, Va., and X-energy, LLC, of Greenbelt, Md., were selected from a preliminary... Read More »
The Science and Technology Directorate (S&T) of the Department of Homeland Security (DHS) awarded $959,305 to the University of Washington’s Applied Physics Laboratory this week to create testing criteria for a COVID-19 digital contact tracing app.
The award was granted through the Silicon... Read More »
A Stewardship and Access Plan Development Guide for countering the spread of antibiotic-resistant superbugs was developed and released this week by CARB-X, some of its leading funders and major antibacterial researchers.
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator... Read More »
As the debate over AstraZeneca’s AZD1222 COVID-19 vaccine rages in Europe, the results of a phase three trial in the United States have shown the vaccine to be 79 percent effective at preventing symptomatic COVID-19 and 100 percent effective at preventing severe cases and hospitalization.
The... Read More »
Nuclear Threat Initiative (NTI) and Munich Security Conference (MSC) personnel recently collaborated to convene 19 current and former global leaders and experts to address reducing high-consequence biological threats.
The endeavor was offered in conjunction with the MSC’s “Beyond... Read More »
Two Georgetown University infectious disease experts maintain vaccines alone may not be enough to control the COVID-19 pandemic.
Angela L. Rasmussen and Saskia V. Popescu, faculty affiliates of the university's Center for Global Health Science and Security, noted that protecting against the... Read More »
Warning that antibiotic resistance is one of the greatest public health threats of the age, the Infectious Diseases Society of America (IDSA) and several partner organizations wrote to House leaders last week urging them to create a comprehensive One Health approach to counter the rising... Read More »
Following the suspension of AstraZeneca’s COVID-19 vaccine by several European countries this week, owing to reports of rare types of blood clots emerging among the vaccinated, the World Health Organization (WHO) has recommended that vaccinations continue.
While the European Union suspensions... Read More »
Moderna announced Tuesday that it has started its study of the COVID-19 vaccine in children.
Called the KidCOVE study, Moderna began Phase 2/3 of its study by administering the vaccine in children from 6 months to less than 12 years of age. The study is being done in collaboration with the... Read More »
Roche recently announced the launch of a new cobas SARS-CoV-2 Variant Set 1 Test to detect and differentiate between viral variants, recognizing the growing prevalence of SARS-CoV-2 variants, such as those first seen in the United Kingdom, South Africa, and Brazil.
“Viruses naturally evolve... Read More »
AstraZeneca announced plans this week to supply up to 500,000 additional doses of AZD7442, an under-development, long-acting antibody combination meant for use against COVID-19, modifying an existing agreement with the U.S. government.
Specifically, the agreement was reached with the Departments... Read More »
Sanofi Pasteur and Translate Bio launched a Phase 1/2 clinical trial last week for an mRNA COVID-19 vaccine candidate known as MRT5500, hoping for interim results in the third quarter of 2021.
The united efforts of the vaccine and mRNA therapeutics companies include parallel preclinical studies... Read More »
The first candidates were dosed this week as part of a phase one study of mRNA-1283, a new mRNA COVID-19 vaccine from Moderna, Inc.
Unlike its predecessor, which has proved highly effective against the original strain of the virus, this new vaccine candidate is meant to solve a major hiccup to... Read More »
Drugmaker AstraZeneca defended the safety of its COVID-19 vaccine after three more European countries said they would suspend the use of the vaccine.
Over the weekend, Germany, Ireland, and The Netherlands announced they would stop using the vaccine temporarily over concerns about the vaccine's... Read More »
World Health Organization (WHO) officials recently touted the progression of the ACT- Accelerator, noting the initiative has driven progress to accelerate the end of the COVID-19 pandemic.
The initiative was initiated in April 2020 by the WHO, the European Commission, France, and The Bill &... Read More »
Harvard University has secured $775,000 in Department of Homeland Security (DHS) Science and Technology Directorate S&T funds to aid the agency's Blue Campaign.
The funds have been earmarked for the university's T.H. Chan School of Public Health to conduct research and evaluate the impact of the... Read More »
Results are in from the latest trials of NVX-CoV2373, Novavax, Inc.’s COVID-19 vaccine candidate, and while it only provided 55.4 percent efficacy in a region beset by the South African variant, it displayed 96.4 percent efficacy against the original strain and 86.3 percent against the United... Read More »
While thankful for the support for system upgrades the newly introduced House LIFT America Act demonstrates, American 9-1-1 groups are concerned that elements of it could prove wasteful and delay and complicate deployment of a Next Generation 9-1-1 nationwide.
“The infrastructure bill is a... Read More »
Democrats on the House Energy and Commerce (E&C) Committee unveiled a sweeping, $312 billion bill known as the LIFT America Act last week that, among other things, would invest in America’s health infrastructure.
“As our nation combats COVID-19 and a severe economic downturn, the LIFT... Read More »
In a study funded by the Mayo Clinic and published in the journal Clinical Infectious Diseases last week, researchers determined that after two doses of mRNA vaccines for COVID-19, asymptomatic patients are less likely to be infected and unknowingly spread the virus.
After two doses of mRNA... Read More »
The single-shot Johnson & Johnson COVID-19 vaccine will be available in more places worldwide now, thanks to a conditional marketing authorization granted by the European Commission and emergency use authorization from the World Health Organization (WHO).
The decisions followed similar approval... Read More »
The National Institutes of Health (NIH) is espousing the benefits of an AEG 12 mosquito protein study authorities said could help develop treatments to combat life-threatening viruses.
Researchers at the NIH's National Institute of Environmental Health Sciences (NIEHS) used X-ray crystallography... Read More »
A study focused on determining whether patients would benefit from a booster for the Moderna, Inc. COVID-19 vaccine has enrolled and dosed its first participants this week.
Moderna’s mRNA COVID-19 vaccine is currently in use across the U.S. and has shown high efficacy against the original... Read More »
Building on its efforts during the ongoing COVID-19 pandemic, the Coalition for Epidemic Preparedness Innovations (CEPI) has proposed a $3.5 billion plan to reduce or eliminate future pandemic and epidemic risk through preparedness investment over the next five years.
The organization has sought... Read More »
A professor from Johns Hopkins Center for Health and Security testified before the Maryland General Assembly on the certification of gene synthesis providers and manufacturers of gene synthesis equipment.
Dr. Gigi Gronvall -- senior scholar at the Johns Hopkins Center for Health Security and... Read More »
Research and development company Battelle announced Tuesday that it had developed a microneutralization assay that uses live SARS-CoV-2 virus to analyze the neutralizing response against the virus in human serum samples.
The assay allows the company to test samples from vaccine clinical trials.... Read More »
CARB-X could award up to $3.5 million, plus up to $18.5 million for successful development milestones, to Affinivax for a vaccine for Staphylococcus aureus bacterial infections, for which treatment options are currently limited.
No vaccine presently exists for S. aureus, despite the high threat... Read More »
The Biomedical Advanced Research and Development Authority (BARDA) and MediciNova, Inc. seek to use a new partnership to repurpose the anti-inflammatory MN-166, better known as ibudilast, for use against acute respiratory distress syndrome (ARDS) and chlorine exposure.
Traditionally, ibudilast... Read More »
Valneva and Pfizer are getting set to launch a new Phase 2 study on VLA-15, their vaccine candidate for Lyme disease.
The study, VLA15-221, builds on previous positive Phase 2 studies. It incorporates new dose regimens and is anticipated to be the final Phase 2 study before deciding to progress... Read More »